ArticleBreast cancer research and treatment2019

Synergistic anti-cancer activity of CDK4/6 inhibitor palbociclib and dual mTOR kinase inhibitor MLN0128 in pRb-expressing ER-negative breast cancer.

Takuro Yamamoto et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.